TVTX - Travere Therapeutics, Inc.

QQQ $ 468.28 $ 9.96 (2.17 %)

DIA $ 409.73 $ 1.01 (0.25 %)

SPY $ 554.79 $ 5.63 (1.03 %)

TLT $ 100.61 $ -0.08 (-0.08 %)

GLD $ 232.25 $ -0.37 (-0.16 %)

Previous Close

$ 12.24

Open

$ 12.63

Bid

$ 12.22 x 100

Ask

$ 12.25 x 100

Day's Range

$ 12.15 - $ 12.64

52 Week Range

$ 5.12 - $ 14.07

Volume

1,316,503

Average Volume

Market Cap

936.26M

Beta (5Y Monthly)

$ 0.90

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-01-2024	06-30-2024	10-Q
2	05-06-2024	03-31-2024	10-Q
3	02-20-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	02-23-2023	12-31-2022	10-K
8	10-27-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	02-24-2022	12-31-2021	10-K
12	10-29-2021	09-30-2021	10-Q
13	07-29-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	03-01-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	07-31-2020	06-30-2020	10-Q
18	05-11-2020	03-31-2020	10-Q
19	02-24-2020	12-31-2019	10-K
20	10-30-2019	09-30-2019	10-Q
21	08-06-2019	06-30-2019	10-Q
22	05-07-2019	03-31-2019	10-Q
23	02-26-2019	12-31-2018	10-K
24	11-01-2018	09-30-2018	10-Q
25	08-03-2018	06-30-2018	10-Q
26	05-01-2018	03-31-2018	10-Q
27	02-27-2018	12-31-2017	10-K
28	11-07-2017	09-30-2017	10-Q
29	08-09-2017	06-30-2017	10-Q
30	05-05-2017	03-31-2017	10-Q
31	03-01-2017	12-31-2016	10-K
32	11-04-2016	09-30-2016	10-Q
33	08-05-2016	06-30-2016	10-Q
34	05-05-2016	03-31-2016	10-Q
35	02-26-2016	12-31-2015	10-K
36	11-06-2015	09-30-2015	10-Q
37	08-10-2015	06-30-2015	10-Q
38	05-11-2015	03-31-2015	10-Q
39	03-11-2015	12-31-2014	10-K
40	11-13-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Canaccord Genuity Maintains Buy on Travere...
09/10/2024 15:05:17

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target fr...

This United States Steel Analyst Turns Bul...
09/09/2024 13:17:23

Guggenheim Upgrades Travere Therapeutics t...
09/09/2024 11:01:52

Guggenheim analyst Vamil Divan upgrades Travere Therapeutics (NASDAQ:TVTX) from Neutral to Buy and announces $25 price target.

Analyst Ratings For Travere Therapeutics
09/06/2024 21:00:37

Citigroup Maintains Buy on Travere Therape...
09/06/2024 18:47:09

Citigroup analyst Carly Kenselaar maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $...

quanex-building-products-posts-better-than-expected-results-joins-zumiez-guidewire-software-smartsheet-and-other-big-stocks-moving-higher-on-friday

Quanex Building Products Posts Better-Than...
09/06/2024 14:11:39

B of A Securities Maintains Buy on Travere...
09/06/2024 13:03:55

B of A Securities analyst Greg Harrison maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

nio-to-rally-around-65-here-are-10-top-analyst-forecasts-for-friday

NIO To Rally Around 65%? Here Are 10 Top A...
09/06/2024 12:16:38

HC Wainwright & Co. Maintains Buy on Trave...
09/06/2024 11:22:13

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

Trading Halt: Halt status updated at 7:05:...
09/05/2024 23:05:07

Travere Says FDA Has Granted Full Approval...
09/05/2024 21:36:01

FILSPARI was granted accelerated approval in February 2023 based on the surrogate marker of proteinuria. Full approval is based...

Trading Halt: Halted at 4:34:47 p.m. ET - ...
09/05/2024 20:34:51

JP Morgan Maintains Overweight on Travere ...
08/13/2024 12:29:09

JP Morgan analyst Anupam Rama maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

HC Wainwright & Co. Maintains Buy on Trave...
08/05/2024 19:24:21

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

Barclays Maintains Overweight on Travere T...
08/02/2024 14:07:53

Barclays analyst Carter Gould maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

Expert Ratings For Travere Therapeutics
08/02/2024 14:00:23

Piper Sandler Maintains Neutral on Travere...
08/02/2024 13:55:24

Piper Sandler analyst Allison Bratzel maintains Travere Therapeutics (NASDAQ:TVTX) with a Neutral and raises the price targe...

Wedbush Maintains Outperform on Travere Th...
08/02/2024 13:08:14

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from ...

Travere Therapeutics Files Mixed Securitie...
08/01/2024 21:38:37

Travere Therapeutics Q2 2024 Adj. EPS $(0....
08/01/2024 20:49:23

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of ...